deltatrials
Completed NA INTERVENTIONAL NCT00330213

Effects of Red Wine and Cognac on Coronary Circulation

Sponsor: Tampere University

Conditions Healthy
Updated 5 times since 2017 Last updated: May 24, 2006 Started: Oct 31, 2004 Completion: Apr 30, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Healthy and is currently completed. Tampere University leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

Moderate consumption of red wine is associated with reduced coronary artery disease mortality. Cardioprotective effects of red wine may be partly related to its ability to improve endothelial function. Red wine increases endothelium-dependent flow-mediated dilatation of the brachial artery acutely after ingestion. Moreover, a heavy dose of red wine (ethanol 1.0 g/kg) has been shown to increase coronary flow reserve (CFR) as measured with transthoracic Doppler echocardiography. CFR depicts the relative increase of coronary blood flow in response to maximal myocardial hyperemia induced by adenosine. It is reduced in atherosclerosis and various conditions associated with the dysfunction of coronary microcirculation, such as diabetes and hypercholesterolemia. Both ethanol and antioxidative polyphenols have been implicated in beneficial endothelial effects of red wine. However, their relative contributions remain uncertain in vivo. It has been suggested that red wine has stronger vasoactive properties than other alcohol beverages, and even de-alcoholized red wine may be sufficient to improve flow-mediated dilatation of the brachial artery. Cognac is also known to contain polyphenols, but its effects on coronary circulation have not been evaluated. The purpose of this randomized controlled cross-over study was to determine with transthoracic echocardiography whether moderate doses of red wine improve CFR in response...

Moderate consumption of red wine is associated with reduced coronary artery disease mortality. Cardioprotective effects of red wine may be partly related to its ability to improve endothelial function. Red wine increases endothelium-dependent flow-mediated dilatation of the brachial artery acutely after ingestion. Moreover, a heavy dose of red wine (ethanol 1.0 g/kg) has been shown to increase coronary flow reserve (CFR) as measured with transthoracic Doppler echocardiography. CFR depicts the relative increase of coronary blood flow in response to maximal myocardial hyperemia induced by adenosine. It is reduced in atherosclerosis and various conditions associated with the dysfunction of coronary microcirculation, such as diabetes and hypercholesterolemia.

Both ethanol and antioxidative polyphenols have been implicated in beneficial endothelial effects of red wine. However, their relative contributions remain uncertain in vivo. It has been suggested that red wine has stronger vasoactive properties than other alcohol beverages, and even de-alcoholized red wine may be sufficient to improve flow-mediated dilatation of the brachial artery. Cognac is also known to contain polyphenols, but its effects on coronary circulation have not been evaluated.

The purpose of this randomized controlled cross-over study was to determine with transthoracic echocardiography whether moderate doses of red wine improve CFR in response to adenosine in healthy humans. We also studied contributions of ethanol and antioxidants by comparing the effects of equal doses of alcoholic and de-alcoholized red wine, and cognac on the plasma antioxidant capacity and CFR.

Status Flow

~Jan 2017 – ~Apr 2019 · 27 months · monthly snapshotCompleted~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

5 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Apr 2019 — Jan 2021 [monthly]

    Completed NA

  5. Jan 2017 — Apr 2019 [monthly]

    Completed NA

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tampere University
  • University of Turku
Data source: University of Turku

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations